FDA Sevabertinib Accelerated Approval 2026: Hyrnuo, HER2-Mutated NSCLC & Regulatory Compliance Guide

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

The FDA action, dated September 9, 2026, expands the existing Hyrnuo indication, which was previously granted accelerated approval in November 2025 for patients with HER2 TKD-mutated NSCLC who had received prior systemic therapy.

The expanded approval is particularly relevant for pharmaceutical companies, oncology developers, clinical teams and regulatory professionals because it combines several important regulatory considerations:

Accelerated approval → biomarker-defined patient selection → companion diagnostic considerations → postmarketing verification → safety monitoring → labeling compliance

The prescribing information includes warnings and precautions for diarrhea, hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, left ventricular dysfunction, ocular toxicity, pancreatic enzyme elevation and embryo-fetal toxicity.

What Happened with FDA's Sevabertinib Approval?

On September 9, 2026, FDA granted accelerated approval to Sevabertinib for adults with locally advanced or metastatic non-squamous NSCLC whose tumors contain HER2 (ERBB2) TKD activating mutations detected using an FDA-authorized test.

The approval expands the therapeutic setting for Hyrnuo beyond the prior-treatment population included in the November 2025 accelerated approval.

The FDA evaluated efficacy using data from SOHO-01 (NCT05099172), an open-label, single-arm, multicenter, multi-cohort clinical trial.

For patients with locally advanced or metastatic NSCLC with HER2 TKD activating mutations who had not received prior systemic therapy, FDA reported:

• 69 patients evaluated
• 75% objective response rate (ORR)
• 95% confidence interval: 64%–85%
• 73% of responders had a duration of response of at least 6 months
• 38% of responders had a duration of response of at least 12 months

Because the approval was granted through the accelerated approval pathway, continued approval is subject to postmarketing requirements intended to verify and describe clinical benefit.

What Is Sevabertinib (Hyrnuo)?

Sevabertinib, marketed as Hyrnuo, is a kinase inhibitor developed by Bayer Healthcare Pharmaceuticals.

The drug targets cancers by activating HER2 (ERBB2) TKD mutations, making biomarker identification an important component of patient selection.

The current FDA indication concerns:

Adult patients → locally advanced/metastatic non-squamous NSCLC → HER2 (ERBB2) TKD activating mutation → FDA-authorized test

This biomarker-defined approach means that regulatory, clinical and diagnostic considerations must be coordinated when implementing the indication.

The recommended dose is 20 mg orally twice daily with food, continued until disease progression or unacceptable toxicity.

Why the Accelerated Approval Pathway Matters

FDA accelerated approval allows certain drugs addressing serious conditions to receive approval based on a surrogate endpoint or intermediate clinical measure that is reasonably likely to predict clinical benefit.

For Sevabertinib, FDA's September 2026 decision was supported by objective response rate and duration of response data from SOHO-01.

However, accelerated approval also creates ongoing regulatory obligations.

FDA's current accelerated-approval listing identifies Study SOHO-02 as the postmarketing requirement for Hyrnuo. The ongoing randomized clinical trial is intended to verify and describe clinical benefit, with a projected completion date of October 31, 2029.

This creates a continuing compliance framework:

Accelerated approval → postmarketing study → clinical benefit verification → FDA regulatory assessment

HER2 Mutation Testing and Patient Selection

The indication is restricted to tumors containing HER2 (ERBB2) TKD activating mutations detected by an FDA-authorized test.

Therefore, appropriate biomarker testing is central to implementation.

Regulatory teams should consider:

• FDA-authorized diagnostic testing
• HER2 mutation identification
• Test performance and validation
• Specimen handling
• Laboratory procedures
• Biomarker reporting
• Patient-selection documentation
• Alignment between diagnostic labeling and drug labeling

FDA previously approved the Oncomine Dx Target Test as a companion diagnostic to aid in identifying HER2 TKD activating mutations in patients who may be eligible for Sevabertinib under the earlier indication.

Key Safety Concerns Identified by FDA

FDA's prescribing information contains multiple warnings and precautions that are important for clinical use and pharmacovigilance planning.

1. Diarrhea

Hyrnuo can cause severe diarrhea.

Patients should be instructed to begin appropriate antidiarrheal management at the first sign of diarrhea or increased bowel movement frequency and maintain fluid and electrolyte intake.

Dose interruption, reduction or permanent discontinuation may be required depending on severity.

2. Hepatotoxicity

Sevabertinib can cause hepatotoxicity.

FDA labeling recommends monitoring liver function tests, including ALT, AST and total bilirubin, before treatment and during therapy.

Regulatory and clinical teams should ensure appropriate laboratory monitoring and dose-management procedures are reflected in applicable materials.

3. Interstitial Lung Disease/Pneumonitis

ILD/pneumonitis is another important safety concern.

Patients should be monitored for new or worsening respiratory symptoms such as:

• Dyspnea
• Cough
• Fever

FDA labeling states that Hyrnuo should be discontinued upon confirmation of ILD/pneumonitis.

4. Left Ventricular Dysfunction

The updated prescribing information includes left ventricular dysfunction among the warnings and precautions requiring attention in the clinical management of patients receiving Hyrnuo.

5. Ocular Toxicity

New or worsening ocular symptoms require prompt clinical assessment.

FDA labeling advises referral to an ophthalmologist when appropriate, with treatment interruption, dose reduction or discontinuation depending on severity.

6. Pancreatic Enzyme Elevation

FDA labeling also identifies elevations in pancreatic enzymes as a safety concern.

Monitoring of amylase and lipase is recommended during treatment, with dose modification based on severity.

7. Embryo-Fetal Toxicity

Sevabertinib can cause fetal harm.

The prescribing information includes recommendations concerning reproductive potential and effective contraception because of the potential embryo-fetal risk.

Key Regulatory Considerations for Pharmaceutical Companies

Accelerated Approval vs Traditional Approval

For Sevabertinib, FDA's accelerated approval is accompanied by a postmarketing requirement involving SOHO-02, making lifecycle regulatory management an important consideration.

What Does the 2026 Approval Mean for Regulatory Teams?

The expanded indication creates several practical considerations for pharmaceutical and biotechnology organizations.

1. Review of the Updated Indication

Regulatory teams should ensure that product materials accurately reflect the expanded patient population and biomarker requirements.

2. Assess Companion Diagnostic Alignment

Drug and diagnostic strategies should remain aligned with the FDA-authorized testing requirements associated with the indication.

3. Update Safety Materials

Safety information should reflect the current prescribing information, including warnings for diarrhea, hepatotoxicity, ILD/pneumonitis, left ventricular dysfunction, ocular toxicity, pancreatic enzyme elevation and embryo-fetal toxicity.

4. Maintain Postmarketing Commitment Tracking

Organizations should maintain documented systems for tracking required postmarketing activities and regulatory milestones.

5. Strengthen Pharmacovigilance

Safety monitoring systems should be capable of identifying, evaluating and reporting relevant adverse events in accordance with applicable requirements.

6. Review of Promotional and Medical Communications

External and internal communications should remain consistent with the FDA-approved indication and prescribing information.

FAQs

1. What is Hyrnuo?

Hyrnuo is the brand name for Sevabertinib, a kinase inhibitor developed by Bayer Healthcare Pharmaceuticals.

2. What did FDA approve in September 2026?

FDA granted accelerated approval for adults with locally advanced or metastatic non-squamous NSCLC whose tumors have HER2 (ERBB2) TKD activating mutations detected by an FDA-authorized test.

3. Is this Sevabertinib first FDA approval?

No. FDA previously granted accelerated approval in November 2025 for patients with HER2 TKD-mutated NSCLC who had received prior systemic therapy.

4. What clinical study supported the expanded indication?

FDA evaluated efficacy using data from SOHO-01, an open-label, single-arm, multicenter, multi-cohort study.

5. What is the recommended dose?

The recommended dose is 20 mg orally twice daily with food, until disease progression or unacceptable toxicity.

6. What are the major safety concerns?

FDA labeling includes warnings and precautions for diarrhea, hepatotoxicity, ILD/pneumonitis, left ventricular dysfunction, ocular toxicity, pancreatic enzyme elevation and embryo-fetal toxicity.

7. Is there a postmarketing requirement?

Yes. FDA identifies SOHO-02 as the ongoing randomized clinical trial intended to verify and describe clinical benefit. The current FDA accelerated-approval listing gives an October 31, 2029, projected completion date.

Conclusion

The September 2026 FDA accelerated approval of Sevabertinib (Hyrnuo) expands the regulatory and clinical use of a targeted therapy for patients with HER2 (ERBB2) TKD activating mutation-positive non-squamous NSCLC.

The approval highlights several interconnected areas of pharmaceutical compliance:

Biomarker identification + diagnostic strategy + accelerated approval + clinical evidence + safety monitoring + labeling + postmarketing commitments

For organizations involved in oncology drug development and commercialization, regulatory compliance does not end with FDA approval.

Ongoing attention to postmarketing requirements, pharmacovigilance, safety labeling, diagnostic alignment, clinical documentation and regulatory intelligence remains essential throughout the product lifecycle.

As FDA continues to monitor accelerated approvals and targeted oncology therapies, companies should maintain systems capable of demonstrating compliance with current FDA requirements and postmarketing commitments.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports pharmaceutical and biotechnology organizations with regulatory strategy, compliance, clinical and safety documentation, and lifecycle regulatory support.

Our support can include:

• FDA Regulatory Strategy
• Accelerated Approval Regulatory Support
• Oncology Regulatory Consulting
• Clinical Regulatory Support
• Drug Labeling & Compliance Review
• Pharmacovigilance Support
• Postmarketing Commitment Management
• Companion Diagnostic Regulatory Support
• Regulatory Submission Support
• Medical & Regulatory Writing
• Regulatory Intelligence
• Inspection & Audit Readiness
• Lifecycle Management Support
• Compliance Gap Assessment

Maven Regulatory Solutions — Science. Compliance. Impact.